PP63 Predictive Value Of Intermediate Endpoints For Overall Survival In High-Risk Localized And Locally Advanced Prostate Cancer
Uwe Siebert, Francesco De Solda, Kimberly Hofer, James McCallion, Sharon A. McCarthy, Suneel D. Mundle, Mir-Masoud Pourrahmat, Victoria Wan, Beate Jahn · 2025
Read PP63 Predictive Value Of Intermediate Endpoints For Overall Survival In High-Risk Localized And Locally Advanced Prostate Cancer by Uwe Siebert, Francesco De Solda, Kimberly Hofer, James McCallion, Sharon A. McCarthy, Suneel D. Mundle, Mir-Masoud Pourrahmat, Victoria Wan, Beate Jahn (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768663.txt.
Description
Uwe Siebert and eight co-authors test whether early outcome signs can stand in for long term survival in high risk prostate cancer. The disease grows slowly, so trials that wait for deaths take many years. The team asked if signs such as time without spread or a clean scan after treatment could predict the survival gain from a drug.
They gathered one hundred thirty-seven studies with tens of thousands of patients and linked each early sign to survival. Links were only fair, and none met the strict bar set by a German health body. Forecast checks still caught most true results. The authors say more work, with real world data, is needed before early signs can replace survival in formal reviews.
Catalog record
| CREATOR | Uwe Siebert, Francesco De Solda, Kimberly Hofer, James McCallion, Sharon A. McCarthy, Suneel D. Mundle, Mir-Masoud Pourrahmat, Victoria Wan, Beate Jahn |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |